

Title: Analgesia for Retinopathy of Prematurity Screening: A Systematic Review.

Running head: Analgesia for ROP Screening: systematic review

Authors: Arun J. Thirunavukarasu^{1,2} BA (Cantab.), Refaat Hassan^{1,3} BA (Cantab.), Shalom V. Savant^{1,4} BA (Cantab.), Duncan L. Hamilton^{5,6} MSc FRCA FFPMRCA FRCS.

Affiliations: ¹University of Cambridge School of Clinical Medicine, ²Corpus Christi College, University of Cambridge, ³Sidney Sussex College, University of Cambridge, ⁴St John's College, University of Cambridge; ⁵James Cook University Hospital, Middlesbrough; ⁶University of Sunderland School of Medicine.

Corresponding author: Arun Thirunavukarasu, Corpus Christi College, Cambridge, CB2 1RH, United Kingdom. ajt205@cam.ac.uk

ORCIDs: Arun James Thirunavukarasu (<https://orcid.org/0000-0001-8968-4768>), Shalom Savant (<https://orcid.org/0000-0002-8464-5708>), Duncan Lee Hamilton (<https://orcid.org/0000-0003-2132-4867>).

Author contributions:

AJT conceived, designed, and led coordination on the study. AJT undertook preliminary literature searches and designed the search strategy. AJT, RH, and SS contributed to screening and study selection. AJT, RH, and SS conducted data extraction and risk of bias analysis. AJT and RH performed data analysis and produced figures. AJT and DLH discussed the implications of results and prepared the manuscript. DLH provided advice throughout the project and edited the final draft. All authors approved the final draft manuscript submitted for publication.

Acknowledgements:

The authors extend their thanks to Louise Allen (Cambridge University Hospitals NHS Foundation Trust) for providing insight into ROP screening and neonatal ophthalmological examination. We thank Aaron Limonard (University of Cambridge School of Clinical Medicine) and Viral Gudiwala (University of Cambridge School of Clinical Medicine) for their feedback regarding our submitted manuscript.

Funding: None to declare.

Conflicts of interest: The authors declare they have no conflicts of interest to disclose.

Data availability: All data presented in the manuscript can be provided upon request.

Abstract

Background and Aims

Premature neonates require regular ophthalmological examination, generally indirect ophthalmoscopy, to screen for retinopathy of prematurity (ROP). Conventional analgesia is provided with topical anaesthetic eyedrops and oral sugar solution, but neonates still experience significant pain. Here, the literature base was examined to evaluate the usefulness of other pharmacological analgesics.

Materials and Methods

A systematic review was undertaken, adhering to a PROSPERO preregistered protocol in accordance with PRISMA guidelines (identifier CRD42022302459). Electronic databases were searched for primary research articles on pharmacological pain interventions used for ROP screening in neonates. The primary outcome measure was pain scores recorded using validated pain scoring tools, with and without pharmacological interventions in neonates during eye examination. For analysis, studies were separated into two categories: topical anaesthesia and alternative pharmacological treatments.

Results

Eleven studies met the inclusion criteria. Topical analgesia, oral paracetamol, and intranasal fentanyl were found to be effective in reducing the pain of eye examination. Oral morphine and inhaled nitrous oxide had no significant effect on premature infant pain profile (PIPP) scores during indirect ophthalmoscopy.

Discussion

In addition to topical anaesthesia, premedication with oral paracetamol is recommended during

screening examination for ROP. The routine use of fentanyl is not recommended due to the risk of potential side effects. Non-pharmacological measures, such as sweet oral solutions and comfort techniques may also be employed. Further research is required to determine whether the use of nitrous oxide has a role, and to develop a safe and effective analgesic strategy to fully ameliorates the pain of ROP screening.

Keywords: retinopathy of prematurity, analgesic, neonatal, indirect ophthalmoscopy, eye examination, topical anaesthesia, opioids, paracetamol, nitrous oxide, screening tools

Introduction

Retinopathy of prematurity (ROP) is a vasoproliferative disease of the retina characterised by incomplete development of the retinal blood vessels. It is the foremost preventable cause of childhood blindness worldwide¹. During normal gestation development of the retinal vessels proceeds peripherally from the head of the optic nerve, driven by hypoxic conditions *in utero*. Following premature birth the associated relative hyperoxia promotes abnormal vascular growth into the vitreous humour, which can lead to fibrovascular retinal detachment². Early diagnosis and treatment is essential before complications ensue^{1,3}. Treatment options aim to facilitate development of retinal vasculature and prevent pathological intravitreal angiogenesis. These range from destructive cryotherapy or laser photocoagulation of the avascular portion of the retina, to inhibition of angiogenesis with anti-vascular endothelial growth factor (anti-VEGF) therapy⁴. In all cases, prompt management is essential for favourable outcomes⁴. To identify cases soon enough for effective treatment, regular screening is recommended for infants born before 31 weeks gestational age, or below 1500g gestational weight^{1,5,6}. Although newer techniques such as digital retinal imaging exist, with potential for artificial intelligence (AI) assistance⁷, the mainstay of screening is currently indirect ophthalmoscopy to visualise the whole retina⁸. If present, ROP is classified according to retinal location (zone); degree of disease at the vascular-avascular junction (stage); and circumferential extent of disease⁹.

Sources of pain during ROP screening include insertion of an eyelid speculum to provide access to the pupil, bright light to illuminate the fundus, and scleral indentation due to manipulation of the eye during examination^{8,10-12}. Exposure of neonates to painful procedures may have implications for future health and development¹³⁻¹⁷, and screening for ROP has been specifically

associated with physiological stress and increased rates of apnoeic episodes¹⁸. As ROP screening is conducted regularly, until retinal vascularisation progresses over a sufficient portion of the retina⁵, offering safe and effective analgesia for the procedure is important. Efficacy of analgesics in neonates can be evaluated through use of a context-specific validated scoring tool¹⁹, such as the Premature Infant Pain Profile (PIPP), revised in 2014, which uses seven indicators to generate a score out of 21^{20,21}. Scores of 7 or above are an indication for intervention, either comfort measures ($7 \leq \text{PIPP score} \leq 12$) or pharmacological analgesia (PIPP score ≥ 13)¹⁹.

Recommendations for pain relief for ROP screening vary, but generally include topical anaesthesia, most often proxymetacaine (proparacaine), and non-pharmaceutical measures such as pacifiers, swaddling, and oral sucrose^{6,23}. Many other pharmaceutical and non-pharmaceutical interventions have been described, but no clinically validated intervention or array of interventions has been demonstrated to fully ameliorate the pain of the procedure²⁴. For pain relief in a more general context, some centres recommend paracetamol for PIPP scores greater than 6, and opioids for scores greater than 12²², with topical anaesthesia being recommended if feasible¹⁹. Specific pharmacokinetic consideration for prescribing analgesics is necessary as screening commences while neonates are still premature in gestational age^{1,5,6}.

While previous literature reviews have looked at analgesic strategies for ROP screening, none have looked specifically at pharmacological interventions, and meta-analysis is complicated by significant heterogeneity in non-pharmacological management and pain assessment²⁴. This review sets out to provide an updated summary of the evidence supporting pharmaceutical analgesic interventions, ranging from well-established topical anaesthesia²⁵ to less conventional

oral and nasal drugs²⁶⁻²⁸, to evaluate their efficacy without confounding effects of non-pharmacological interventions, which are the mainstay of neonatal pain management, but vary widely between centres. Using PICOS, the objectives of this review are summarised as follows:

Participants: premature neonates undergoing screening for retinopathy of prematurity.

Interventions: pharmacological analgesia used to reduce the procedural pain caused by ROP screening.

Comparisons: comparing procedural pain with and without particular pharmacological interventions.

Outcomes: procedural pain, assayed with a validated scoring tool such as PIPP.

Study design: controlled trials, preferably but not necessarily randomised and blinded.

Materials and Methods

The systematic review protocol was prospectively registered in PROSPERO

(CRD42022302459)²⁹, and PRISMA guidance was adhered to throughout conducting and

reporting this review³⁰. A search of The Cochrane Library, MEDLINE (via PubMed), Embase

(via OVID), and Scopus was undertaken on January 14, 2022, with no initial restrictions placed

on publication date, language, or publication status. The search string was as follows:

“retinopathy of prematurity” AND (“analgesia” OR “pain”) in the title, abstract, and/or

keywords. Studies were also incorporated from previous reviews on similar topics^{23,24,31-35}, and

study protocols from The Cochrane Library were checked for subsequent publications

disseminating results. Study selection is illustrated in Fig. 1: duplicates were initially removed

by a single researcher; title and abstract screening was conducted by two researchers; full text

screening was conducted by two researchers. Both researchers appraised every paper at both

screening stages; to resolve disagreement, discussion was used to establish consensus, and a

third researcher cast a deciding vote if disagreement was still not resolved. Inclusion criteria during title and abstract screening were: 1. Some reference to retinopathy of prematurity (ROP); 2. Some reference to screening or examination; 3. Some reference to procedural pain.

The ranked criteria for inclusion during full-text screening were as follows:

1. Written in the English language.
2. Is a primary research article.
3. The study population consists of neonates undergoing ROP screening.
4. The same ROP screening technique was used across experimental arms.
5. A pharmacological pain-relieving intervention was included in the study.
6. Pain assessment was included as an outcome variable.

For articles satisfying the inclusion criteria, two reviewers performed data extraction. Data were extracted solely from text and tables; no extrapolation from graphs was performed. Specifically, the data collected were citation details; the number of subjects, both in total, and in each experimental arm; a comprehensive description of the trialled intervention (*i.e.* drug, route, dose, timing relative to procedure); a comprehensive description of the 'base' analgesic interventions and examination technique common to all experimental arms; pain scores during procedure (if multiple pain scores provided, peak mean pain score was extracted) for each experimental arm; and *p* value for *t*-test or ANOVA comparing the pain scores in each experimental population. A risk of bias analysis was performed by two researchers for each study, with an evaluation as high risk, low risk, or unclear risk in the following seven domains, derived from The Cochrane Collaboration's tool for assessing risk of bias in randomised trials³⁶: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias

(*e.g.* conflicting interests, but specified if applicable). In cases of disagreement, the third researcher acted as arbiter, following discussion.

Included studies were grouped into two categories based on the intervention being tested: (conventional) topical anaesthesia and (less conventional) oral and nasal anaesthesia. For each study, examination technique was described comprehensively with an emphasis on analgesic measures (pharmacological and non-pharmacological) undertaken in addition to the trialled method, to illustrate heterogeneity in clinical practice. Due to this confounding heterogeneity, meta-analysis was excluded; studies exhibit a wide range of baseline interventions, and combine interventions in many different ways²⁴. Instead, a narrative synthesis was organised around summary statistics (outlined above) for each group of studies, and mean changes in PIPP score, weighted by sample size, where multiple studies tested a similar analgesic. Where multiple studies tested a similar intervention, evidence for and against a positive analgesic effect was listed alongside any concerns regarding bias or statistical power. Conclusions were drawn based on the preponderance of evidence, with uncertainty highlighted as encountered. Larger p values and smaller effect sizes were interpreted as less certain evidence of a positive analgesic effect, as were studies with a higher risk of bias. To evaluate the risk of publication bias, p values were graphed, with a peak at or below $p=0.05$ being indicative of bias towards ‘statistically significant’ results, perhaps inflating evidence in favour of a positive effect.

Results

The search identified 561 papers, from which eleven studies were selected for further analysis (Fig. 1). PICOS characteristics and risk of bias analysis for those eleven studies are presented in Table 1 and Figure 2, respectively. One of the studies was adjudged to exhibit a high risk of bias,

due to single-blind design, lack of placebo control, and loss of data due to poor quality videos⁴⁴.

Two studies were categorised as unclear in terms of risk of bias, due to use of a minimisation sequence rather than randomisation and early trial cessation, and due to potential early unblinding and early trial cessation^{37,43}. For further analysis, studies were grouped according to whether they trialled topical anaesthesia instilled into the conjunctival sac, or analgesics via the oral or nasal routes.

Topical anaesthesia

Three of four studies evaluating topical anaesthesia, proxymetacaine 0.5% in every case, reported lower pain scores in infants treated with topical anaesthesia compared with placebo, with weighted mean PIPP reduction of 1.66, and p values ranging from 0.001-0.1 (Table 2)^{27,38,39,41}. One study compared topical anaesthesia with 0.5% proxymetacaine to sweet oral solution and found no statistically significant difference ($p=0.165$) between them in terms of pain relief⁴¹. In all cases, pain relief was incomplete, with mean PIPP scores greater than 7 in every experimental arm; one study even exhibited mean PIPP scores greater than 14, beyond a recognised threshold for additional pharmacological intervention. In one study, mean PIPP scores were calculated from more granular data that provided average scores for separate eyes in both experimental groups⁴¹.

Alternative pharmacological treatments

Various alternative analgesics have been trialled: paracetamol (acetaminophen), morphine, fentanyl, and nitrous oxide (Table 3)^{26-28,40,42-44}. Administration routes included oral, intranasal, and inhaled gas, with no intravenous medication trialled. Evidence for paracetamol is generally positive, although no statistically significant effect was found in a trial comparing 15 mg.kg⁻¹

paracetamol given orally 30 minutes pre-procedure to both a breastmilk pre-feed and no-feed control, in a trial deemed to exhibit a high risk of bias⁴⁴. In contrast, positive effects were recorded for 15 mg.kg⁻¹ paracetamol given 60 minutes pre-procedure versus water control⁴², and 15 mg.kg⁻¹ paracetamol given 30 minutes pre-procedure versus water and oral sucrose⁴⁰. Another study comparing 20 mg.kg⁻¹ paracetamol 60 minutes pre-procedure to placebo exhibited a limited positive effect but did not reach the authors' threshold for statistical significance, perhaps due to a much smaller sample size, and assessment of pain after the procedure, rather than during examination²⁶. In these studies, paracetamol conferred a weighted mean PIPP reduction of 2.18, *p* values ranging from 0.001-0.75.

Three studies tested the effect of opioid analgesics. One, using 200 mcg.kg⁻¹ morphine sulphate given orally one hour pre-procedure, exhibited a positive effect but failed to meet the authors' criteria for statistical significance, likely due to a small sample size of 18²⁶. A larger study of 31 infants, which administered 100 mcg.kg⁻¹ morphine sulphate given orally one hour pre-procedure, found no significant difference between morphine and placebo groups⁴³. A weighted mean PIPP reduction of 0.60, with *p* values of 0.083 and 0.66 do not provide convincing evidence for the efficacy of oral morphine. However, in the single study testing intra-procedural 2 mcg.kg⁻¹ intranasal fentanyl, a significant and relatively large positive effect was noted²⁸.

Finally, one study tested the use of an oxygen and nitrous oxide gas mixture delivered via a nasal cannula during the procedure in a cohort of 40 neonates, finding almost identical pain levels between this group and a control group treated with a placebo consisting of an oxygen and nitrogen gas mixture²⁷.

As with the topical anaesthesia trials, no intervention conferred complete pain relief, as the mean PIPP scores were greater than 7 in every experimental arm. While most evidence points towards paracetamol and nasal fentanyl having a significant analgesic effect, the evidence suggests oral morphine and nitrous oxide gas have little to no effect.

Discussion

This review reveals that a range of pharmacological analgesics have been trialled as measures to reduce the pain associated with ROP screening. There is most evidence for topical anaesthesia and paracetamol, with fewer studies exploring the use of opioids or nitrous oxide. The preponderance of evidence supports positive analgesia being conferred by intra-procedure topical proxymetacaine, pre-procedure oral paracetamol, and intra-procedure intranasal fentanyl, whereas all published evidence suggests that pre-procedure oral morphine and intra-procedure inhaled nitrous oxide do not provide effective pain relief. The evidence was generally concordant with the above conclusions, although one of four studies testing proxymetacaine did not exhibit a significant effect, and two of four studies testing paracetamol similarly finding no significant effect. In the single study testing nitrous oxide, it is difficult to determine the actual inspired nitrous oxide fraction using this delivery method. While it is possible to deliver Entonox® more effectively using an anaesthetic breathing circuit, this can be challenging during indirect ophthalmoscopy²⁷.

Risk-benefit analysis is necessary to determine which apparently effective analgesics are suitable for routine use in ROP screening. Of the three effective agents described above, topical anaesthesia is already widely utilised, and is mentioned in national guidelines⁵. Pre-procedure paracetamol is not so widely used, but is already indicated for lower pain levels than local

anaesthesia¹⁹, and is generally considered safe. Recommended doses of 20-25 mg.kg⁻¹ paracetamol are higher than three of four studies reviewed here, and carry very low risks of hepatic or renal toxicity, though lower doses may be appropriate to account for preterm infants with lower clearance⁴⁵. Fentanyl is a potent opioid reserved for more severe pain. It is generally used to induce deep sedation or anaesthesia¹⁹, and its side effects include respiratory depression, bradycardia, and chest wall rigidity^{46,47}. Use of fentanyl is generally restricted to specialists in anaesthesia, and it may not be a justifiable choice for routine use, despite exhibiting effectiveness in a single study²⁸. To further reduce pain, clinicians could instead focus on non-pharmacological interventions, such as swaddling, nesting, and oral sugar solution (e.g. sucrose, dextrose)^{24,31,32,34,48}.

It is justifiable to generalise conclusions made here to all neonatal eye examinations, although ROP screening is one of the most common reasons they are undertaken⁴⁹. However, conclusions cannot be extended to ophthalmological procedures, including cryotherapy and laser treatment (which may be indicated in ROP). This review is limited by the lack of quantitative meta-analysis, not undertaken due to difficulties in combining studies with different examination techniques and analgesic measures outside the tested intervention, and relatively small number of studies, making network meta-analysis overly reliant on modelled results. Weighted mean PIPP reductions calculated above may not accurately represent the effect of a given analgesic for similar reasons. The review is also limited by the relatively small number of studies exploring the effects of pharmacological analgesics, of which most had sample sizes lower than fifty. The distribution of studies across the full possible range of p values, despite a peak below $p=0.05$, suggests that publication bias is minimal. However, there are relatively few studies

testing any of the above interventions, and sample sizes frequently small enough to raise concerns of a lack of statistical power, and increased risk of random significant results.

In summary, our recommendation based on the above evidence would be to incorporate pre-procedure oral paracetamol and intra-procedure topical anaesthesia with proxymetacaine to ameliorate the pain of ROP screening. These interventions should be combined with non-pharmacological measures such as swaddling, nesting, and oral sugar solution, which have proven efficacy and form the basis of pain management in this setting²⁴. Further investigation is necessary to engineer analgesic solutions, either pharmacological or otherwise, avoiding the side effects and sedation associated with opioids²⁴. Other unanswered questions include the optimal dosage of paracetamol and whether the use of nitrous oxide has an effective role. Trials should focus on robust design to avoid bias and maximise reliability, as well as a prospective power analysis to ensure a sufficient sample size is tested.

References

1. Fierson WM, AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology, AMERICAN ACADEMY OF OPHTHALMOLOGY, AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS. Screening Examination of Premature Infants for Retinopathy of Prematurity. *Pediatrics*. 2018;142(6):e20183061. doi:[10.1542/peds.2018-3061](https://doi.org/10.1542/peds.2018-3061)
2. Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. *Ophthalmology*. 2015;122(1):200-210. doi:[10.1016/j.optha.2014.07.050](https://doi.org/10.1016/j.optha.2014.07.050)

3. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020--the right to sight. *Bull World Health Organ.* 2001;79(3):227-232.
4. Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. *Am J Ophthalmol.* 2020;218:208-213.
doi:[10.1016/j.ajo.2020.05.025](https://doi.org/10.1016/j.ajo.2020.05.025)
5. Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists, British Association of Perinatal Medicine, BLISS. *Guideline for the Screening and Treatment of Retinopathy of Prematurity.*; 2008.
6. Jefferies A. Retinopathy of prematurity: Recommendations for screening. *Paediatr Child Health.* 2010;15(10):667-670.
7. Coyner AS, Swan R, Brown JM, et al. Deep Learning for Image Quality Assessment of Fundus Images in Retinopathy of Prematurity. *AMIA Annu Symp Proc.* 2018;2018:1224-1232.
8. Moral-Pumarega MT, Caserío-Carbonero S, De-La-Cruz-Bértolo J, Tejada-Palacios P, Lora-Pablos D, Pallás-Alonso CR. Pain and stress assessment after retinopathy of prematurity screening examination: Indirect ophthalmoscopy versus digital retinal imaging. *BMC Pediatrics.* 2012;12. doi:[10.1186/1471-2431-12-132](https://doi.org/10.1186/1471-2431-12-132)
9. Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Third Edition. *Ophthalmology.* 2021;128(10):e51-e68.
doi:[10.1016/j.opthta.2021.05.031](https://doi.org/10.1016/j.opthta.2021.05.031)

10. Slevin M, Murphy JFA, Daly L, O'Keefe M. Retinopathy of prematurity screening, stress related responses, the role of nesting. *British Journal of Ophthalmology*. 1997;81(9):762-764. doi:[10.1136/bjo.81.9.762](https://doi.org/10.1136/bjo.81.9.762)
11. Mehta M, Adams G, Bunce C, Xing W, Hill M. Pilot study of the systemic effects of three different screening methods used for retinopathy of prematurity. *Early human development*. 2005;81(4):355-360. doi:[10.1016/j.earlhumdev.2004.09.005](https://doi.org/10.1016/j.earlhumdev.2004.09.005)
12. Mataftsi A, Lithoxopoulou M, Seliniotaki AK, et al. Avoiding use of lid speculum and indentation reduced infantile stress during retinopathy of prematurity examinations. *Acta Ophthalmologica*. 2022;100(1). doi:[10.1111/aos.15085](https://doi.org/10.1111/aos.15085)
13. Carbajal R, Rousset A, Danan C, et al. Epidemiology and treatment of painful procedures in neonates in intensive care units. *JAMA*. 2008;300(1):60-70. doi:[10.1001/jama.300.1.60](https://doi.org/10.1001/jama.300.1.60)
14. Brummelte S, Grunau RE, Chau V, et al. Procedural pain and brain development in premature newborns. *Ann Neurol*. 2012;71(3):385-396. doi:[10.1002/ana.22267](https://doi.org/10.1002/ana.22267)
15. Grunau RE. Neonatal pain in very preterm infants: long-term effects on brain, neurodevelopment and pain reactivity. *Rambam Maimonides Med J*. 2013;4(4):e0025. doi:[10.5041/RMMJ.10132](https://doi.org/10.5041/RMMJ.10132)
16. Vinall J, Grunau RE. Impact of repeated procedural pain-related stress in infants born very preterm. *Pediatr Res*. 2014;75(5):584-587. doi:[10.1038/pr.2014.16](https://doi.org/10.1038/pr.2014.16)
17. Walker SM. Long-term effects of neonatal pain. *Semin Fetal Neonatal Med*. 2019;24(4):101005. doi:[10.1016/j.siny.2019.04.005](https://doi.org/10.1016/j.siny.2019.04.005)

18. Mitchell AJ, Green A, Jeffs DA, Roberson PK. Physiologic effects of retinopathy of prematurity screening examinations. *Advances in Neonatal Care*. 2011;11(4):291-297.
doi:[10.1097/ANC.0b013e318225a332](https://doi.org/10.1097/ANC.0b013e318225a332)
19. Witt N, Coynor S, Edwards C, Bradshaw H. A Guide to Pain Assessment and Management in the Neonate. *Curr Emerg Hosp Med Rep*. 2016;4:1-10. doi:[10.1007/s40138-016-0089-y](https://doi.org/10.1007/s40138-016-0089-y)
20. Ballantyne M, Stevens B, McAllister M, Dionne K, Jack A. Validation of the premature infant pain profile in the clinical setting. *Clin J Pain*. 1999;15(4):297-303.
doi:[10.1097/00002508-199912000-00006](https://doi.org/10.1097/00002508-199912000-00006)
21. Stevens BJ, Gibbins S, Yamada J, et al. The premature infant pain profile-revised (PIPP-R): initial validation and feasibility. *Clin J Pain*. 2014;30(3):238-243.
doi:[10.1097/AJP.0b013e3182906aed](https://doi.org/10.1097/AJP.0b013e3182906aed)
22. Pasero C. Pain Assessment in Infants and Young Children: Premature Infant Pain Profile. *AJN The American Journal of Nursing*. 2002;102(9):105-106.
23. Francis K. What is best practice for providing pain relief during retinopathy of prematurity eye examinations? *Advances in Neonatal Care*. 2016;16(3):220-228.
doi:[10.1097/ANC.0000000000000267](https://doi.org/10.1097/ANC.0000000000000267)
24. Disher T, Cameron C, Mitra S, Cathcart K, Campbell-Yeo M. Pain-Relieving Interventions for Retinopathy of Prematurity: A Meta-analysis. *Pediatrics*. 2018;142(1).
doi:[10.1542/peds.2018-0401](https://doi.org/10.1542/peds.2018-0401)
25. Saunders RA, Miller KW, Hunt HH. Topical anesthesia during infant eye examinations: does it reduce stress? *Ann Ophthalmol*. 1993;25(12):436-439.

26. Manjunatha C, Ibbanesebhor S, Rennix C, Fisher H, Abara R. Pain control during retinopathy of prematurity screening: double-blind, randomised, placebo-controlled study. *Infant*. 2009;5(5):155-158.
27. Mandel R, Ali N, Chen J, Galic I, Levesque L. Nitrous oxide analgesia during retinopathy screening: a randomised controlled trial. *Archives of disease in childhood Fetal and neonatal edition*. 2012;97(2):F83-7. doi:[10.1136/adc.2011.210740](https://doi.org/10.1136/adc.2011.210740)
28. Sindhur M, Balasubramanian H, Srinivasan L, Kabra N, Agashe P, Doshi A. Intranasal fentanyl for pain management during screening for retinopathy of prematurity in preterm infants: a randomized controlled trial. *Journal of perinatology*. 2020;40(6):881-887. doi:[10.1038/s41372-020-0608-2](https://doi.org/10.1038/s41372-020-0608-2)
29. Thirunavukarasu A, Hassan R, Savant S. Systematic review of pharmacological analgesic interventions for neonatal eye examinations such as for retinopathy of prematurity screening. Published online 2022. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022302459
30. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:[10.1136/bmj.n71](https://doi.org/10.1136/bmj.n71)
31. Samra HA, McGrath JM. Pain management during retinopathy of prematurity eye examinations: a systematic review. *Adv Neonatal Care*. 2009;9(3):99-110. doi:[10.1097/ANC.0b013e3181a68b48](https://doi.org/10.1097/ANC.0b013e3181a68b48)
32. Sun X, Lemyre B, Barrowman N, O'Connor M. Pain management during eye examinations for retinopathy of prematurity in preterm infants: A systematic review. *Acta Paediatrica*,

International Journal of Paediatrics. 2010;99(3):329-334. doi:[10.1111/j.1651-2227.2009.01612.x](https://doi.org/10.1111/j.1651-2227.2009.01612.x)

33. Dempsey E, McCreery K. Local anaesthetic eye drops for prevention of pain in preterm infants undergoing screening for retinopathy of prematurity. *Cochrane Database of Systematic Reviews*. 2011;(9). doi:[10.1002/14651858.CD007645.pub2](https://doi.org/10.1002/14651858.CD007645.pub2)
34. Kandasamy Y, Smith R, Wright IMR, Hartley L. Pain relief for premature infants during ophthalmology assessment. *Journal of AAPOS*. 2011;15(3):276-280.
doi:[10.1016/j.jaapos.2011.03.009](https://doi.org/10.1016/j.jaapos.2011.03.009)
35. Stevens B, Yamada J, Lee GY, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. *Cochrane Database of Systematic Reviews*. 2013;2013(1).
doi:[10.1002/14651858.CD001069.pub4](https://doi.org/10.1002/14651858.CD001069.pub4)
36. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. doi:[10.1136/bmj.d5928](https://doi.org/10.1136/bmj.d5928)
37. Marsh VA, Young WO, Dunaway KK, et al. Efficacy of topical anesthetics to reduce pain in premature infants during eye examinations for retinopathy of prematurity. *Ann Pharmacother*. 2005;39(5):829-833. doi:[10.1345/aph.1E476](https://doi.org/10.1345/aph.1E476)
38. Mehta M, Mansfield T, VanderVeen D. Effect of topical anesthesia and age on pain scores during retinopathy of prematurity screening. *Journal of perinatology*. 2010;30(11):731-735.
doi:[10.1038/jp.2010.36](https://doi.org/10.1038/jp.2010.36)
39. Cogen M, Parker J, Sleep T, Elsas F, Metz T, McGwin G. Masked trial of topical anesthesia for retinopathy of prematurity eye examinations. *Journal of AAPOS: the official publication*

of the american association for pediatric ophthalmology and strabismus. 2011;15(1):45-48.

doi:[10.1016/j.jaapos.2010.11.011](https://doi.org/10.1016/j.jaapos.2010.11.011)

40. Seifi F, Peirovifar A, Gharehbaghi MM. Comparing the Efficacy of Oral Sucrose and Acetaminophen in Pain Relief for Ophthalmologic Screening of Retinopathy of Prematurity. *American Journal of Medical Sciences and Medicine*. 2013;1(2):24-27.
doi:[10.12691/ajmsm-1-2-2](https://doi.org/10.12691/ajmsm-1-2-2)
41. Nesargi S, Nithyanandam S, Rao S, Nimbalkar S, Bhat S. Topical anesthesia or oral dextrose for the relief of pain in screening for retinopathy of prematurity: a randomized controlled double-blinded trial. *Journal of tropical pediatrics*. 2015;61(1):20-24.
doi:[10.1093/tropej/fmu058](https://doi.org/10.1093/tropej/fmu058)
42. Kabataş E, Dursun A, Beken S, Dilli D, Zenciroğlu A, Okumuş N. Efficacy of Single Dose Oral Paracetamol in Reducing Pain During Examination for Retinopathy of Prematurity: a Blinded Randomized Controlled Trial. *Indian journal of pediatrics*. 2016;83(1):22-26.
doi:[10.1007/s12098-015-1765-8](https://doi.org/10.1007/s12098-015-1765-8)
43. Hartley C, Moultrie F, Hoskin A, et al. Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial. *Lancet*. 2018;392(10164):2595-2605. doi:[10.1016/S0140-6736\(18\)31813-0](https://doi.org/10.1016/S0140-6736(18)31813-0)
44. Naik A, D'Lima A, Sreekumar K, Silveira M. Efficacy of expressed breast milk alone or in combination with paracetamol in reducing pain during ROP screening: a randomized controlled trial. *Journal of clinical neonatology*. 2021;10(2):73-78.
doi:[10.4103/jcn.jcn_198_20](https://doi.org/10.4103/jcn.jcn_198_20)

45. Pacifici GM, Allegaert K. Clinical Pharmacology of Paracetamol in Neonates: A Review. *Curr Ther Res Clin Exp*. 2014;77:24-30. doi:[10.1016/j.curtheres.2014.12.001](https://doi.org/10.1016/j.curtheres.2014.12.001)
46. Anand KJS, Hall RW, Desai N, et al. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. *Lancet*. 2004;363(9422):1673-1682. doi:[10.1016/S0140-6736\(04\)16251-X](https://doi.org/10.1016/S0140-6736(04)16251-X)
47. Hall RW, Shbarou RM. Drugs of choice for sedation and analgesia in the neonatal ICU. *Clin Perinatol*. 2009;36(1):15-26. doi:[10.1016/j.clp.2008.09.007](https://doi.org/10.1016/j.clp.2008.09.007)
48. Campbell-Yeo M, Benoit B. Use of morphine before retinopathy of prematurity examinations. *The Lancet*. 2018;392(10164):2521-2523. doi:[10.1016/S0140-6736\(18\)32324-9](https://doi.org/10.1016/S0140-6736(18)32324-9)
49. Mansoor N, Mansoor T, Ahmed M. Eye pathologies in neonates. *Int J Ophthalmol*. 2016;9(12):1832-1838. doi:[10.18240/ijo.2016.12.22](https://doi.org/10.18240/ijo.2016.12.22)

Figure and table legends

Figure 1. PRISMA flow-chart depicting how studies were selected for inclusion in this systematic review: initial search, duplicate exclusion, title and abstract screening, and full-text screening. Duplicates were removed by a single researcher; screening was conducted by two researchers, with discussion and a third researcher acting as an arbiter to resolve disagreement.

Figure 2. Risk of bias analysis for all of the included studies. Six domains were derived from the Cochrane Collaboration's tool for assessing risk of bias in randomised trials, and studies were also specifically screened for any other potential sources of bias. For each study, two researchers evaluated the risk of bias, with discussion and a third researcher acting as arbiter to resolve any disagreements.

Citation	Participants	Interventions	Comparisons	Outcomes	Study design
Marsh et al, 2005 ²⁷	22 premature neonates undergoing indirect ophthalmoscopy with scleral depression and wire speculum. All patients swaddled for several minutes before examination and held by a nurse during examination.	Proparacaine HCl 0.5% (2 drops immediately prior to examination).	NaCl 0.5% (2 drops immediately prior to examination).	PIPP measured before (5 min, 1 min) examination and during speculum placement.	Randomised double blind placebo-controlled crossover; two arms.
Manjunatha et al, 2009 ²⁶	18 premature neonates. All patients given one drop 0.5% proparacaine 0.5% in each eye, 5min before examination.	Morphine sulphate 200 mcg.kg ⁻¹ (oral dose 60 min before examination); paracetamol 30 mg.kg ⁻¹ (oral dose 60 min before examination).	Placebo 2 ml.kg ⁻¹ (oral dose 60 min before examination).	PIPP measured before (5 min) and after (5 min, 30 min, 60 min, 120 min, 180 min).	Randomised double blind placebo-controlled crossover; three arms.
Mehta et al, 2010 ³⁸	40 premature neonates undergoing indirect ophthalmoscopy with lid speculum and scleral depression. All patients given non-nutritive pacifier and swaddled during examination.	Proparacaine HCl 0.5% (drops during examination).	Saline (drops during examination).	PIPP measured before (1 min) and after (1 min, 5 min) examinations commenced.	Randomised double blind placebo-controlled crossover; two arms.
Cogen et al, 2011 ³⁹	34 premature neonates undergoing indirect ophthalmoscopy with scleral depression.	Proparacaine HCl 0.5% (drops during examination)	Artificial tears (drops during examination).	PIPP measured after speculum insertion, during initial visualisation of the retina, and after scleral depression.	Randomised double blind placebo-controlled crossover; two arms.

Mandel et al, 2012 ²⁷	40 premature neonates undergoing indirect ophthalmoscopy . All infants swaddled by a nurse throughout examination; one drop proparacaine 0.5% in each eye 1min before examination; 24% sucrose administered orally at the nurse's discretion, starting 1min before local anaesthetic.	50% oxygen and 50% nitrous oxide gas mixture (nasal cannula initiated 5 min before examination).	EMONO 50% oxygen 50% nitrogen gas mixture (nasal cannula initiated 5 min before examination).	PIPP measured after speculum insertion and 30 min after examination.	Randomised double blind placebo-controlled crossover; two arms.
Seifi et al, 2013 ⁴⁰	120 premature neonates undergoing ROP screening. All infants given tetracaine 1% eyedrops prior to examination of each eye.	Paracetamol 15 mg.kg ⁻¹ (oral dose 30 min before examination) and sterile water 0.2 mL (orally administered during examination).	25% sucrose 0.2 mL (orally administered during examination); sterile water 0.2mL (orally administered during examination).	PIPP measured during the first and last 45s of each examination.	Randomised double blind placebo-controlled crossover; three arms.
Nesargi et al, 2015 ⁴¹	20 premature neonates undergoing indirect ophthalmoscopy . All infants given proparacaine 0.5% drops 10 min prior to examination of each eye.	Proparacaine HCl 0.5% (1 eye-drop immediately prior to examination)	25% dextrose 2 mL (oral dose administered 10 min before examination).	PIPP measured during examination of the left eye.	Randomised double blind crossover; two arms.
Kabataş et al, 2016 ⁴²	114 premature neonates undergoing ROP screening. All infants given 0.5% proparacaine applied 30s before examination.	Paracetamol 15 mg.kg ⁻¹ (single oral dose 60 min before examination)	15 mL.kg ⁻¹ sterile water (single oral dose 60min before examination).	PIPP measured during examination of the first eye.	Randomised double blind placebo-controlled crossover; two arms.

Hartley et al, 2018 ⁴³	31 premature neonates undergoing indirect ophthalmoscopy with scleral indenter and eyelid speculum. All infants swaddled before procedure and given 0.5% proxymetacaine drops before insertion of eyelid speculum.	Morphine sulphate 100 mcg.kg ⁻¹ (single oral dose 60 min before examination).	Placebo 100 mcg.kg ⁻¹ (administered via oral syringe or nasogastric tube 60 min before examination).	PIPP-R measured 30s after speculum removed post-examination.	Randomised double blind placebo-controlled crossover; two arms.
Sindhur et al, 2020 ²⁸	111 premature neonates undergoing indirect ophthalmoscopy with scleral indenter and eyelid speculum. All infants given 0.5 ml oral sucrose 24% 1 min prior to examination and 0.5% proparacaine 30s prior.	Fentanyl 2 mcg.kg ⁻¹ (intranasal administration 5 min before examination).	Saline 0.3 mL (intranasal administration 5 min before examination).	PIPP-R measured during and after (1 min, 5 min) examination.	Randomised double blind placebo-controlled crossover; two arms.
Naik et al, 2021 ⁴⁴	120 premature neonates undergoing indirect ophthalmoscopy with scleral indenter and eyelid speculum. All infants given proparacaine drops prior to examination and swaddled during procedure.	Paracetamol 15 mg.kg ⁻¹ (single oral dose 30 min before examination)	Conventional analgesia only; expressed breast milk 2 mL (orally administered 2 min before examination).	PIPP measured before (20s), during, and after (2 min) examination.	Randomised single blind crossover; three arms.

Table 1. PICOS table summarising the eleven studies included in the systematic review. Semi-colons separate distinct experimental arms. PIPP = premature infant pain profile; PIPP-R = premature infant pain profile revised. Procedures are described in as much detail as provided by the study full-text.

Citation	N	Experimental Arms	Pain Scores	<i>p</i>
Cogen et al, 2011 ³⁹	34	(A) Proxymetacaine	PIPP _A = 10.4	0.1
		(B) Artificial tears	PIPP _B = 12.0	
Marsh et al, 2005 ²⁷	22	(A) Proxymetacaine	PIPP _A = 11	0.001
		(B) Saline drops	PIPP _B = 13.5	
Mehta et al, 2010 ³⁸	40	(A) Proxymetacaine	PIPP _A = 10.375	0.027
		(B) Saline drops	PIPP _B = 11.725	
Nesargi et al, 2015 ⁴¹	20	(A) Proxymetacaine	PIPP _A = 14.75	0.165
		(B) Sweet taste	PIPP _B = 14.55	

Table 2. Results of randomised trials evaluating topical anaesthesia for ameliorating the pain of ROP screening. PIPP = premature infant pain profile.

Citation	N	Experimental Arms	Pain Scores	<i>p</i>
Kabataş et al, 2016 ⁴²	114	(A) TA and paracetamol	PIPP _A = 12	0.01
		(B) TA and water	PIPP _B = 14	
Naik et al, 2021 ⁴⁴	120	(A) TA and paracetamol	PIPP _A = 15.83	0.72
		(B) TA and breastmilk/formula prefeed	PIPP _B = 15.44	
		(C) TA	PIPP _C = 15.74	
Seifi et al, 2013 ⁴⁰	120	(A) TA and sweet taste	PIPP _A = 12.9	<0.001
		(B) TA and paracetamol	PIPP _B = 9.0	
		(C) TA and water	PIPP _C = 13.7	
Manjunatha et al, 2009 ²⁶	18	(A) TA and paracetamol	PIPP _A = 4.600	0.083
		(B) TA and morphine	PIPP _B = 3.500	
		(C) TA and placebo	PIPP _C = 6.167	
Hartley et al, 2018 ⁴³	31	(A) TA and morphine	PIPP _A = 11.1	0.66
		(B) TA and placebo	PIPP _B = 10.5	
Sindhur et al, 2020 ²⁸	111	(A) TA and sucrose and fentanyl	PIPP _A = 8.3	<0.001

		(B) TA and sucrose and saline	PIPP _B = 11.5	
Mandel et al, 2012 ²⁷	40	(A) TA and sweet taste and N2O/ O2 gas	PIPP _A = 8.5	0.94
		(B) TA and sweet taste and N2/O2 gas	PIPP _B = 8.4	

Table 3. Results of randomised trials evaluating alternative pharmaceuticals, defined as anything other than topical anaesthesia, for ameliorating the pain of ROP screening. TA = topical anaesthesia; N₂O = nitrous oxide; O₂ = oxygen; N₂ = nitrogen; PIPP = premature infant pain profile.